PL2591785T3 - Zastosowanie 5-androstano(alkilo)-3,5,6-triolu do wytwarzania leków neuroprotekcyjnych - Google Patents

Zastosowanie 5-androstano(alkilo)-3,5,6-triolu do wytwarzania leków neuroprotekcyjnych

Info

Publication number
PL2591785T3
PL2591785T3 PL11803155T PL11803155T PL2591785T3 PL 2591785 T3 PL2591785 T3 PL 2591785T3 PL 11803155 T PL11803155 T PL 11803155T PL 11803155 T PL11803155 T PL 11803155T PL 2591785 T3 PL2591785 T3 PL 2591785T3
Authority
PL
Poland
Prior art keywords
androstane
triol
alkyl
production
neuroprotective drugs
Prior art date
Application number
PL11803155T
Other languages
English (en)
Inventor
Guangmei Yan
Haiyan Hu
Tiandong Leng
Hanfei Sang
Jingxia Zhang
Pengxin Qiu
Shujia Zhou
Jiesi Chen
Xiuhua You
Original Assignee
Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Cellprotek Pharmaceutical Co., Ltd. filed Critical Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Publication of PL2591785T3 publication Critical patent/PL2591785T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
PL11803155T 2010-07-09 2011-07-08 Zastosowanie 5-androstano(alkilo)-3,5,6-triolu do wytwarzania leków neuroprotekcyjnych PL2591785T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010102241733A CN101884638B (zh) 2010-07-09 2010-07-09 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
EP11803155.8A EP2591785B1 (en) 2010-07-09 2011-07-08 Use of 5-androstane (alkyl)-3,5,6 -triol in preparing neuroprotective drugs

Publications (1)

Publication Number Publication Date
PL2591785T3 true PL2591785T3 (pl) 2017-08-31

Family

ID=43070839

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11803155T PL2591785T3 (pl) 2010-07-09 2011-07-08 Zastosowanie 5-androstano(alkilo)-3,5,6-triolu do wytwarzania leków neuroprotekcyjnych

Country Status (22)

Country Link
US (2) US8809309B2 (pl)
EP (1) EP2591785B1 (pl)
JP (1) JP5681931B2 (pl)
KR (1) KR101463477B1 (pl)
CN (1) CN101884638B (pl)
AU (1) AU2011276800B2 (pl)
BR (1) BR112012031861B1 (pl)
CA (1) CA2802133C (pl)
CY (1) CY1118789T1 (pl)
DK (1) DK2591785T3 (pl)
ES (1) ES2620754T3 (pl)
HR (1) HRP20170418T1 (pl)
HU (1) HUE032159T2 (pl)
LT (1) LT2591785T (pl)
PL (1) PL2591785T3 (pl)
PT (1) PT2591785T (pl)
RS (1) RS55845B1 (pl)
RU (1) RU2541093C2 (pl)
SG (1) SG186135A1 (pl)
SI (1) SI2591785T1 (pl)
SM (1) SMT201700208T1 (pl)
WO (1) WO2012003802A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
CN105012313B (zh) * 2014-04-25 2018-03-16 广州市赛普特医药科技股份有限公司 5α‑雄甾‑3β,5,6β‑三醇及其类似物在预防或治疗低压缺氧引起的高原病中的应用
CN103626819B (zh) * 2012-03-08 2016-01-20 广州市赛普特医药科技有限公司 雄甾-3β,5α,6β-三醇的晶型化合物及其制备方法
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
CN113350359B (zh) * 2017-12-29 2022-08-16 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用
CN109985049B (zh) * 2017-12-29 2022-02-22 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇在制备治疗脑小血管病的药物中的应用
US11516173B1 (en) * 2018-12-26 2022-11-29 Snap Inc. Message composition interface
CN118845793A (zh) * 2023-04-28 2024-10-29 广州市赛普特医药科技股份有限公司 化合物在预防或治疗放射性脑损伤中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2191576A (en) * 1936-11-21 1940-02-27 Soc Of Chemical Ind 3,5,6-trihydroxy androstane and pregnane compounds
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
JP2007512344A (ja) * 2003-11-24 2007-05-17 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体調節剤
CN1557829A (zh) * 2004-01-19 2004-12-29 复旦大学 化合物5α-雄甾烷-1α,3β,17β-三醇17-醋酸酯和衍生物,及其制备方法
US8354396B2 (en) * 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101683348B (zh) * 2008-09-23 2012-07-04 中山大学 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用
CN101884638B (zh) 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN101961311B (zh) 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法

Also Published As

Publication number Publication date
SG186135A1 (en) 2013-01-30
EP2591785A4 (en) 2013-12-11
AU2011276800A9 (en) 2013-11-21
CN101884638B (zh) 2011-11-09
PT2591785T (pt) 2017-04-04
US20130157993A1 (en) 2013-06-20
SI2591785T1 (sl) 2017-07-31
LT2591785T (lt) 2017-06-26
SMT201700208T1 (it) 2017-05-08
CA2802133C (en) 2014-01-14
US9320743B2 (en) 2016-04-26
RU2012151400A (ru) 2014-08-20
CA2802133A1 (en) 2012-01-12
JP5681931B2 (ja) 2015-03-11
RU2541093C2 (ru) 2015-02-10
CY1118789T1 (el) 2018-03-07
RS55845B1 (sr) 2017-08-31
WO2012003802A1 (zh) 2012-01-12
US20140329790A1 (en) 2014-11-06
DK2591785T3 (en) 2017-03-27
JP2013529657A (ja) 2013-07-22
EP2591785B1 (en) 2017-01-04
AU2011276800B2 (en) 2013-11-21
ES2620754T3 (es) 2017-06-29
KR101463477B1 (ko) 2014-11-19
HUE032159T2 (en) 2017-09-28
BR112012031861A2 (pt) 2016-11-08
HRP20170418T1 (hr) 2017-06-16
AU2011276800A1 (en) 2013-01-10
EP2591785A1 (en) 2013-05-15
CN101884638A (zh) 2010-11-17
KR20130038286A (ko) 2013-04-17
BR112012031861B1 (pt) 2020-02-04
US8809309B2 (en) 2014-08-19

Similar Documents

Publication Publication Date Title
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
FR17C1040I2 (fr) Derive antiviraux de 2,5-dibenzimidazol-5-yl-1-phenyl-pyrrolidine
PL2591785T3 (pl) Zastosowanie 5-androstano(alkilo)-3,5,6-triolu do wytwarzania leków neuroprotekcyjnych
LT3447061T (lt) Farmacinė vaisto forma, apimanti 5-fluor-2'-deoksiuridinofosforamidato darinį, skirtą naudoti vėžio gydymui
SMT201700008B (it) Composizione farmaceutica
EP2704573A4 (en) AMINOMETHYL biaryl BENZOTRIAZOL DERIVATIVES
DK3246018T3 (da) Farmaceutisk sammensætning
PL2630108T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
EE201300005A (et) Ravimkoostis
EP2699091A4 (en) 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS
EP2721029A4 (en) Imidazopyridine-2-ON DERIVATIVES
EP2546231A4 (en) alkylamine
EP2692715A4 (en) COMPOSITION OF GAS-PRODUCING AGENTS
EP2930176A4 (en) Hydantoin derivative
EP2628733A4 (en) ACYLBENZEN DERIVATIVE
BR302012001925S1 (pt) "configuração aplicada em calota"
ITMI20110184A1 (it) Composti fotosensibilizzanti "metal free"
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
IT1405996B1 (it) Procedimento per la preparazione di 2,5-diaminotoluolo
DK2851075T3 (da) Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
EP2796453A4 (en) DERIVATIVES OF HYDROXYMETHYLFURFURAL
BR112013010195A2 (pt) "empanque"
BR112013010223A2 (pt) "piranosidade temperatura- estável"
BR112012029887A2 (pt) composição farmacêutica
EP2859191A4 (en) SHOVEL CARRIER ARRANGEMENT